A biopharmaceutical company involved in the discovery.

Flavin, Ph.D., chairman and ceo of Advanced Life Sciences. Robert Hancock, Professor in the Division of Immunology and Microbiology at UBC, who is a leader in neuro-scientific peptide antibiotics and includes a history of conducting innovative and highly regarded antimicrobial research. He functions closely with the innovative Center for Drug Study and Advancement on the formulation and preclinical development. At the July 26th FDA workshop centered on antibiotic resistance Hancock has been invited as a loudspeaker.Dr. Kirsten Bibbins-Domingo, vice chair of the U.S. Preventive Services Task Force, said, ‘When the task force reviewed the evidence on PSA screening for prostate malignancy in 2011, what we found is definitely that there is a very small potential benefit and significant potential harms.’ Many prostate cancers found simply by PSA screening are slow-growing and not life-threatening, she explained. ‘However, there is currently no way to determine which cancers will probably threaten a man’s health insurance and that may not,’ she said. Barocas disagreed. ‘The policy of screening nobody is throwing the infant away with the bathwater,’ he said. Some men are in high risk for prostate cancer and should be screened, he said. These include guys with a family group history of prostate cancer, and black men.